Download PDF
Semin Thromb Hemost 2002; 28(5): 425-430
DOI: 10.1055/s-2002-35282
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Methods for the Monitoring of Direct Thrombin Inhibitors

Gerd Hafner1 , Markus Roser2 , Matthias Nauck2
  • 1Zentrum für Labormedizin und Mikrobiologie, Essen, Germany
  • 2Institut für Klinische Chemie, Klinikum der Ernst-Moritz-Arndt-Universität, Greifswald, Germany
Further Information

Publication History

Publication Date:
06 November 2002 (online)

    Permissions and Reprints

ABSTRACT

Direct thrombin inhibitors are available for prophylactic as well as therapeutic purposes. Application of hirudin in therapeutic doses has been shown to require drug monitoring. Currently, most experience is available for recombinant hirudin, but the principle aspects of drug monitoring are the same for all direct thrombin inhibitors. Most frequently, activated partial thromboplastin time (aPTT) and modifications of the activated clotting time (ACT) have been used for the monitoring of hirudin therapy. However, these methods are insensitive at plasma levels higher than 0.6 mg/L of hirudin, so that overdoses may be missed despite monitoring. Correlations between ecarin clotting time (ECT), enzyme immunoassays, and chromogenic substrate assays on one side and global tests on the other side are poor. Fully automated chromogenic substrate-based assays, also available as point-of-care tests (POCT), are more precise and sensitive and are not disturbed by interferents such as heparin and antithrombin. Good correlations can be observed between chromogenic assays and the ECT performed in plasma or whole blood samples. ECT can also be determined with POCT systems. Test characteristics such as imprecision and measuring range are comparable to those of the chromogenic assays. In conclusion, therapy with direct thrombin inhibitors should be monitored with chromogenic assays or ECT.

KEYWORDS

Hirudin - direct thrombin inhibitors - monitoring - ecarin clotting time - chromogenic assay

REFERENCES

  • 1 Antman E M. Hirudin in acute myocardial infarction-safety report from the thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial.  Circulation . 1994;  90 1624-1630
    PubMedGoogle Scholar
  • 2 The Global Use of Strategies To Open occluded coronary arteries (GUSTO) IIA investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994 90: 1631-1637
    Google Scholar
  • 3 Neuhaus K L, von Essen R, Tebbe U. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study: a study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK).  Circulation . 1994;  90 1638-1642
    PubMedGoogle Scholar
  • 4 Greinacher A, Volpel H, Janssens U. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study.  Circulation . 1999;  99 73-80
    CrossrefPubMedGoogle Scholar
  • 5 Eriksson B I, Ekman S, Kälebo P. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393.  Lancet . 1996;  347 635-639
    CrossrefPubMedGoogle Scholar
  • 6 Nowak G, Bucha E, Gööck T, Thieler H, Markwardt F. Pharmacology of r-hirudin in renal impairment.  Thromb Res . 1992;  66 707-715
    CrossrefPubMedGoogle Scholar
  • 7 Bucha E, Markwardt F, Nowak G. Hirudin in haemodialysis.  Thromb Res . 1990;  60 445-455
    CrossrefPubMedGoogle Scholar
  • 8 Vanholder R, Camez A, Veys N. Recombinant hirudin: a specific thrombin inhibiting anticoagulant for hemodialysis.  Kidney Int . 1994;  45 1754-1759
    PubMedGoogle Scholar
  • 9 Lindhoff-Last E, Mosch G, Ehrly A M, Bauersachs R. The influence of recombinant hirudin on clotting and chromogenic coagulation assays (Abst).  Ann Hematol . 1999;  78(Suppl I) A77
    PubMedGoogle Scholar
  • 10 Bauersachs R M, Lindhoff-Last E, Ehrly M. Treatment of hirudin overdosage in a patient with chronic renal failure (Letter).  Thromb Haemost . 1999;  81 323-324
    PubMedGoogle Scholar
  • 11 Irani M S, White H J, Sexon R G. Reversal of hirudin-induced bleeding diathesis by prothrombin complex concentrate.  Am J Cardiol . 1995;  75 422-423
    CrossrefPubMedGoogle Scholar
  • 12 van den Bos A A, Deckers J W, Heyndrickx G R. Safety and efficacy of recombinant hirudin (CGP 39393) versus heparin in patients with stable angina undergoing coronary angioplasty.  Circulation . 1993;  88 2058-2066
    PubMedGoogle Scholar
  • 13 Zoldhelyi P, Webster M WI, Fuster V. Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters.  Circulation . 1993;  88 2015-2022
    PubMedGoogle Scholar
  • 14 Verstraete M, Nurmohamed M, Kienast J. Biological effects of recombinant hirudin (CGP 39393) in human volunteers.  J Am Coll Cardiol . 1993;  22 1080-1088
    PubMedGoogle Scholar
  • 15 Nurmohamed M T, Berckmans R J, Morrien-Salomons W M. Monitoring anticoagulant therapy by activated partial thromboplastin time: hirudin assessment.  Thromb Haemost . 1994;  72 685-692
    PubMedGoogle Scholar
  • 16 Markwardt F. Untersuchungen über den Mechanismus der blutgerinnungshemmenden Wirkung des Hirudins.  Naunyn Schmiedeberg Arch Pharmacol . 1956;  229 389-399
    PubMedGoogle Scholar
  • 17 Markwardt F, Walsmann P. Die Reaktion zwischen Hirudin und Thrombin.  Hoppe Seylers Z Physiol Chem . 1958;  312 85-98
    PubMedGoogle Scholar
  • 18 Griesbach U, Stürzebecher J, Markwardt F. Assay of hirudin in plasma using a chromogenic thrombin substrate assay.  Thromb Res . 1985;  37 347-350
    CrossrefPubMedGoogle Scholar
  • 19 Walsmann P. Einsatz von Hirudin zur Diagnostik von Gerinnungsvorgängen und Thrombin-induzierten Zellreaktionen.  Hämostaseologie . 1991;  11 107-113
    PubMedGoogle Scholar
  • 20 Spannagl M, Bichler J, Birg A, Lill H, Schramm W. Development of a chromogenic substrate assay for the determination of hirudin in plasma.  Blood Coagul Fibrinolysis . 1991;  2 121-127
    PubMedGoogle Scholar
  • 21 Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet 1999 353: 429-438
    Google Scholar
  • 22 Schiele F, Vuillemenot A, Kramarz P. A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis.  Thromb Haemost . 1994;  71 558-562
    PubMedGoogle Scholar
  • 23 Nowak G, Markwardt F. Hirudin in disseminated intravascular coagulation.  Haemostasis . 1991;  21(Suppl 1) 142-148
    PubMedGoogle Scholar
  • 24 Koza M J, Walenga J M, Fareed J, Pifarre R. A new approach in monitoring recombinant hirudin during cardiopulmonary bypass.  Semin Thromb Hemost . 1993;  19 90-96
    PubMedGoogle Scholar
  • 25 Pötzsch B, Madlener K, Seelig C. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass: assessment of the whole blood ecarin clotting time.  Thromb Haemost . 1997;  77 920-925
    PubMedGoogle Scholar
  • 26 Tripodi A, Chantarangkul V, Arbini A A, Moia M, Mannucci P M. Effects of hirudin on activated partial thromboplastin time determined with ten different reagents.  Thromb Haemost . 1993;  70 286-288
    PubMedGoogle Scholar
  • 27 Nowak G, Bucha E. Quantitative determination of hirudin in blood and body fluids.  Semin Thromb Hemost . 1996;  22 197-202
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Walenga J M, Bakhos M, Messmore H L. Comparison of recombinant hirudin and heparin as an anticoagulant in a cardiopulmonary bypass model.  Blood Coagul Fibrinolysis . 1991;  2 105-111
    PubMedGoogle Scholar
  • 29 Lidon R M, Theroux P, Juneau M, Adelman B, Maraganore J. Initial experience with a direct antithrombin, hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects.  Circulation . 1993;  88 1495-1501
    PubMedGoogle Scholar
  • 30 Rupprecht H J, Terres W, Özbek C. Recombinant hirudin (HBW 023) prevents troponin-T release after PTCA in patients with unstable angina.  J Am Coll Cardiol . 1995;  26 1637-1642
    CrossrefPubMedGoogle Scholar
  • 31 Hafner G, Rupprecht H J, Luz M. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.  Eur Heart J . 1996;  17 1207-1215
    PubMedGoogle Scholar
  • 32 Reid III J T, Alving B M. A quantitative thrombin time for determining levels of hirudin and HirulogTM .  Thromb Haemost . 1993;  70 608-616
    PubMedGoogle Scholar
  • 33 Spinner S, Stöffler G, Fink E. Quantitative enzyme-linked immunosorbent assay (ELISA) for hirudin.  J Immunol Methods . 1986;  87 79-83
    CrossrefPubMedGoogle Scholar
  • 34 Bichler J, Fichtl B, Siebeck M, Fritz H. Pharmacokinetics and pharmacodynamics of hirudin in man after single subcutaneous and intravenous bolus administration.  Arzneimittelforschung . 1988;  38 704-710
    PubMedGoogle Scholar
  • 35 Spinner S, Scheffauer F, Maschler R, Stöffler G. A hirudin catching ELISA for quantitating the anticoagulant in biological fluids.  Thromb Res . 1988;  51 617-625
    CrossrefPubMedGoogle Scholar
  • 36 Schlaeppi J M, Vekemans S, Rink H, Chang J Y. Preparation of monoclonal antibodies to hirudin and hirudin peptides. A method for studying the hirudin thrombin interaction.  Eur J Biochem . 1990;  188 463-470
    CrossrefPubMedGoogle Scholar
  • 37 Iyer L, Adam M, Amiral J, Fareed J, Bermes E. Development and validation of two enzyme-linked immunosorbent assay (ELISA) methods for recombinant hirudin.  Semin Thromb Hemost . 1995;  21 184-192
    PubMedGoogle Scholar
  • 38 Berscheid G, Grötsch H, Neubauer H. Determination of r-DNA hirudin and a human thrombin-hirudin complex in plasma samples: enzyme linked immunosorbent assays for hirudin and complex versus chromogenic thrombin substrate assay.  Thromb Res . 1992;  66 33-42
    CrossrefPubMedGoogle Scholar
  • 39 Markwardt F, Hauptmann J, Nowak G, Klessen C, Walsmann P. Pharmacological studies on the antithrombotic action of hirudin in experimental animals.  Thromb Haemost . 1982;  47 226-229
    PubMedGoogle Scholar
  • 40 Markwardt F, Nowak G, Stürzebecher J. Pharmacokinetics and anticoagulant effect of hirudin in man.  Thromb Haemost . 1984;  52 160-163
    PubMedGoogle Scholar
  • 41 Markwardt F, Nowak G, Stürzebecher J, Vogel G. Clinico-pharmacological studies with recombinant hirudin.  Thromb Res . 1988;  52 393-400
    CrossrefPubMedGoogle Scholar
  • 42 Degryse E. Determination of the specific activity of recombinant hirudin.  Thromb Res . 1990;  60 433-443
    CrossrefPubMedGoogle Scholar
  • 43 Stürzebecher J. Methods for determination of hirudin.  Semin Thromb Hemost . 1991;  17 99-102
    PubMedGoogle Scholar
  • 44 Grötsch H, Damm D, Ben Yussef R, Härtel D. Comparison of two methods for the determination of rDNA-hirudin in plasma samples: HPLC vs a chromogenic thrombin substrate assay.  Thromb Res . 1991;  64 273-277
    CrossrefPubMedGoogle Scholar
  • 45 Hafner G, Fickenscher K, Friesen H J. Evaluation of an automated chromogenic substrate assay for the rapid determination of hirudin in plasma.  Thromb Res . 1995;  77 165-173
    CrossrefPubMedGoogle Scholar
  • 46 Bichler J, Siebeck M, Maschler R, Pelzer H, Fritz H. Determination of thrombin-hirudin complex in plasma with an enzyme-linked immunosorbent assay.  Blood Coagul Fibrinolysis . 1991;  2 129-133
    PubMedGoogle Scholar
  • 47 Pötzsch B, Hund S, Madlener K, Unkrig C, Müller-Berghaus G. Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay.  Thromb Res . 1997;  86 373-383
    CrossrefPubMedGoogle Scholar
  • 48 Novoa E, Seegers W H. Mechanisms of alpha-thrombin and beta-thrombin-E formation: use of ecarin for isolation of meizothrombin 1.  Thromb Res . 1980;  18 657-668
    CrossrefPubMedGoogle Scholar
  • 49 Solano C, Cobcroft G, Scott D C. Prediction of vitamin K response using the echis time and echis-prothrombin time ratio.  Thromb Haemost . 1990;  64 353-357
    PubMedGoogle Scholar
  • 50 Koster A, Hansen A, Grauhan O. Hirudin monitoring using TAS ecarin clotting time in patients with heparin-induced thrombocytopenia type II.  J Cardiothorac Vasc Anesth . 2000;  14 249-252
    CrossrefPubMedGoogle Scholar
  • 51 Pernerstorfer T, Hollenstein U, Hansen J B. Lepirudin blunts endotoxin-induced coagulation activation.  Blood . 2000;  95 1729-1734
    PubMedGoogle Scholar
      >